Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 0%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx Corp demonstrated a solid third quarter in 2025, reporting revenue of $21.5 million, which marks a 5% year-over-year increase largely attributed to the continued adoption of the Zephyr Valve for severe emphysema treatment. The company's ability to maintain a gross margin of 75% while narrowing its net loss to $14 million highlights its commitment to operational efficiency, and its gross profit rose to $16.1 million from $15.0 million the previous year. Additionally, the company's international revenue saw a significant 15% increase, indicating robust expansion efforts that, along with disciplined investment strategies and the introduction of new leadership, position Pulmonx for future growth and sustained market presence.

Bears say

Pulmonx Corp reported preliminary Q3 revenue of approximately $21.5 million, indicating a sequential decline compared to Q2’s revenue of $23.9 million, which reflects a weaker growth trajectory and led to a reduction in full-year guidance to $90 million–$92 million. The company faced challenges with execution risk amid changes in management, as it transitioned back to former CEO Glen French and appointed Derrick Sung as COO/CFO. Additionally, pressures on both top-line growth and gross margins, which decreased from 72% in Q2, further contribute to a negative outlook for the company's financial performance.

Pulmonx (LUNG) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 0% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 7 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.